文献速递湿疹皮炎与荨麻疹

揭示欧洲中重度特应性皮炎的真实成本与社会影响

Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-01-01

本文为欧洲特应性皮炎工作组白皮书,系统评估中重度特应性皮炎的整体经济与人文负担及当前诊疗挑战。白皮书提出利益相关方与政策制定者协作改善管理的建议,以实现长期症状控制并降低负担。

要点

  • 瘙痒-搔抓循环是 multifaceted 负担主因,导致睡眠剥夺、污名化与自信问题。
  • 许多患者治疗不足,症状未控制,进一步加重患者、社会与经济负担。

核心结论

  • 中重度特应性皮炎给欧洲患者、社会与医疗体系带来高负担,许多患者治疗不足导致症状未控制并进一步加重负担。
  • 白皮书作者提出利益相关方与政策制定者协作改善特应性皮炎管理、实现长期症状控制的建议,以降低相关成本与负担。

研究设计与样本

  • 欧洲特应性皮炎工作组(由皮肤病学与医疗政策决策专家组成的国际网络)撰写的白皮书。
  • 对中重度特应性皮炎整体经济与人文负担及当前诊疗挑战进行系统评估。

主要发现

  • 欧洲约4.4%的成人及高达18.6%的儿童/青少年患有特应性皮炎,其中20%的病例为中重度。
  • 瘙痒-搔抓循环是 multifaceted 负担的主要原因,导致严重睡眠剥夺、因皮肤外观受到的污名化及自信问题,进而引起心理社会问题并随时间累积,妨碍患者达到「完整生活潜能」。
  • 许多患者治疗不足,导致症状未控制,进一步加重患者、社会与经济负担。

临床怎么用

  • 白皮书作者建议关键利益相关方与政策制定者协作支持改善特应性皮炎管理,以实现更好的疾病控制,从而降低个人、社会与经济负担。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis (AD) is a chronic, auto-immune condition that imposes a high burden on individuals, society, and the healthcare system. Approximately 4.4% of adults and up to 18.6% of children/adolescents have AD in Europe, with 20% of all cases accounting for moderate-to-severe forms. This form of the condition in adults results in annual societal costs across Europe of an estimated €30 billion; €15.2 billion related to missed workdays or reduced work productivity, €10.1 billion related to direct medical costs and €4.7 billion related to personal expenditure of patients/families. AD can also substantially impact physical, emotional, and social quality-of-life. Several studies have shown the debilitating itch-scratch cycle is the main cause of the multifaceted burden, as it causes substantial sleep deprivation and stigmatisation due to the physical appearance of the skin, and confidence issues. These factors lead to psychosocial issues and can cumulate over time and prohibit patients reaching their 'full life potential'. Despite this, many patients with the condition are undertreated, resulting in uncontrolled symptoms and a further strain placed on patients, society, and the economy. The authors of this White Paper comprise the European Atopic Dermatitis Working Group, which is a network of international specialists with expertise in dermatology and healthcare policy decisions. Their programme of action is focused on harnessing their expertise to build consensus, advance research, share knowledge, and ultimately seek to improve AD care outcomes through achieving long-term symptom control. This White Paper presents a systematic evaluation of the overall financial and humanistic burden of moderate-to-severe AD and the current challenges that exist with AD care. It introduces recommendations for how, collaboratively, key stakeholders and policy makers can support improvements in AD management to achieve better disease control, thus reducing the costs and associated burden placed on individuals, society, and the economy.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Augustin M, Misery L, von Kobyletzki L, et al. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2022. PMID: 35801296. doi:10.1111/jdv.18168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。